P432: Barriers to prescribing anti-TNF therapy in inflammatory bowel disease (IBD) across newly industrialised emerging market countries: an analysis of the ‘EXPLORE’ study
ECCO '19 Copenhagen
2019
P433: Aetiologies of iron deficiency-related anaemia in German patients with inflammatory bowel disease
ECCO '19 Copenhagen
2019
P435: Rapidity of symptomatic and inflammatory biomarker improvements following upadacitinib induction treatment: data from the U-ACHIEVE study
ECCO '19 Copenhagen
2019
P436: Darvadstrocel treatment outcomes in Crohn’s disease patients with complex perianal fistulas: the role of TNFi co-treatment in ADMIRE CD
ECCO '19 Copenhagen
2019
P437: Risk of immunomediated adverse events or secondary loss of response to infliximab in elderly patients with inflammatory bowel disease: a cohort study of the ENEIDA registry
ECCO '19 Copenhagen
2019
P438: Lupus-like reactions in patients with inflammatory bowel disease treated with anti-TNFs are rare but insidious adverse events: data from a large single-centre cohort
ECCO '19 Copenhagen
2019
P439: Effectiveness and safety of the sequential use of a second and third anti-TNF agent in patients with inflammatory bowel disease: results from the ENEIDA registry
ECCO '19 Copenhagen
2019
P440: Comparison of infliximab serum levels between venous and capillary blood in paediatric IBD patients using novel blood sampling technology
ECCO '19 Copenhagen
2019
P441: Long-term immunogenicity of vedolizumab in ulcerative colitis and Crohn’s disease (GEMINI Programme)
ECCO '19 Copenhagen
2019
P442: Strictureplasty for Crohn’s disease of the small bowel in the biological era: long-term outcomes and risk factors for site specific recurrence
ECCO '19 Copenhagen
2019
P443: Clinical features, therapeutic requirements, and evolution of patients with Crohn's disease and upper digestive tract involvement (CROHNEX study)
ECCO '19 Copenhagen
2019
P444: Post-induction Infliximab trough levels in severe and moderate paediatric ulcerative colitis: preliminary data of a retrospective, population cohort-based study
ECCO '19 Copenhagen
2019
P445: Prevalence rates of biosimilar discontinuation and switchback to originator biologics following non-medical switching: a meta-analysis of real-world studies
ECCO '19 Copenhagen
2019
P446: Dose escalation with originator infliximab is more common than standard dosing in paediatric IBD: the DEVELOP experience
ECCO '19 Copenhagen
2019
P447: The impact of therapeutic drug monitoring during biosimilar infliximab switch in inflammatory bowel disease
ECCO '19 Copenhagen
2019
P448: Cannabis and cannabinoids for the treatment of inflammatory bowel disease: a systematic review and meta-analysis
ECCO '19 Copenhagen
2019
P449: Selective depletion of LAG3+ cells in T-cell-driven inflammation: a randomised, double-blind, placebo-controlled, FTIH phase I/Ib clinical trial
ECCO '19 Copenhagen
2019
P450: Association of Infliximab trough levels and transmural healing in Crohn’s disease
ECCO '19 Copenhagen
2019